Neuro-Innovators adds Ray Jordan to board as stroke program advances

Neuro-Innovators named communications veteran Ray Jordan to its board as lead preferred shareholder director while the Boston biotech moves ahead with NIV-001, its lead program for chronic stroke recovery. The company recently started dosing patients in a study at Spaulding Rehabilitation Hospital, part of Mass General Brigham.

Why it matters: - Neuro-Innovators is trying to turn a neuroscience platform into a clinical therapy for people recovering from stroke and other neurological injuries. - The board appointment adds senior healthcare, biotech and corporate communications experience as the company pushes its next stage of growth. - The move comes as Neuro-Innovators works to strengthen investor, stakeholder and partnership support around its lead program.

What happened: - Neuro-Innovators appointed Ray Jordan as lead preferred shareholder director on its board of directors. - Jordan is managing director of Elmstead Partners LLC and Putnam Insights LLC. - Neuro-Innovators announced the appointment on Sept. 21, 2026, in Boston. - The company said Jordan will help as it advances NIV-001 in the clinic and prepares for its next stage.

The details: - Neuro-Innovators describes itself as a biotechnology company developing therapies designed to promote neurological recovery after injury and disease. - Jordan previously held senior corporate affairs and communications roles at Moderna, Amgen and Johnson & Johnson. - Jordan also served as senior communications and strategic counsel at Pfizer. - Neuro-Innovators said Jordan has experience across healthcare, technology, biotechnology and consumer industries. - The company said Jordan has been recognized by PRWeek and PRovoke Media. - Neuro-Innovators also said Jordan’s former employers earned honors including FORTUNE's World's Most Admired Companies and the Dow Jones Sustainability Index. - Jordan said Neuro-Innovators is pursuing a goal of helping people recover function after stroke and other neurological injuries. - Jordan said the company has translated a scientific rationale into a capital-efficient clinical program with potential to address a significant unmet need. - Jordan said he will support the company as it advances NIV-001, builds awareness of Neuroplastic Medicine™ and develops partnerships to reach more patients. - Neuro-Innovators recently began dosing patients in a clinical study of NIV-001 at Spaulding Rehabilitation Hospital, part of Mass General Brigham. - NIV-001 is Neuro-Innovators’ lead investigational program for chronic stroke recovery.

Between the lines: - The board pick suggests Neuro-Innovators is prioritizing both clinical execution and outside credibility as it moves a first-in-class program forward. - Jordan’s background points to a role that likely extends beyond governance into communications, reputation and stakeholder strategy. - The company is pairing a clinical update with a leadership announcement, which can help signal momentum to investors and partners.

What's next: - Neuro-Innovators is expected to continue advancing NIV-001 through its clinical study. - The company will likely lean on Jordan’s experience as it builds corporate visibility and seeks future partnerships. - Neuro-Innovators says its longer-term mission is to improve functional outcomes and reduce the burden of neurologic disability.

The bottom line: - Neuro-Innovators is adding a seasoned healthcare communications leader to its board at the same time it pushes its lead stroke-recovery program deeper into the clinic.

More information: Neuro-Innovators | Neuro-Innovators on LinkedIn